Cat. No.
MABL-974
Application
in vivo, SPR, therapeutic, ELISA
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
BIWA4
From
Recombinant Antibody
Specificity
The antibody is specific for CD44v6. The antibody recognises an epitope encoded by variant exon v6 of CD44. CD44v6 is a tumor associated antigen abundantly expressed in head and neck squamous cell carcinomas (HNSCC) and in normal squamous epithelium.
Alternative Names
bivatuzumab; CD44 antigen; CDw44; Epican; Extracellular matrix receptor III; ECMR-III; GP90 lymphocyte homing/adhesion receptor; HUTCH-I; Heparan sulfate proteoglycan; Hermes antigen; Hyaluronate receptor; Phagocytic glycoprotein 1; PGP-1; Phagocytic glycoprotein I; PGP-I
UniProt
P16070
Immunogen
The antibody is the humanized version of the murine BIWA-1.
Application Notes
The binding affinity of the antibody to CD44v6 was measured by surface plasmon resonance. The antibody showed a specificity of tumor localization when administrated together with another anti-CD44v6 antibody in mice in in vivo experiments (Verel et al. 2002; PMID: 11992408). The specificity of the humanized version of the antibody was confirmed by ELISA anlaysis (Kd= 3.4 nM). The antibody had good therapeutic efficacy, biodistribution and tumor uptake in in vivo experiments in mice. Mice treated with 186Re-BIWA 4 showed a decreased in the tumor volume (US6972324B2). The radioactively labelled humanized version of the antibody was employed in a clinical trial in patients with advanced squamous cell carcinoma of the head and neck showing promising antitumor effects (Börjesson et al., 2003; PMID: 14506195).
Antibody First Published
Note on publication
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
